Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for VRTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Research and Development Expense (Annual) Data

View and export this data back to 1991. Start Trial.
Date Value
December 31, 2025 3.754B
December 31, 2024 3.630B
December 31, 2023 3.163B
December 31, 2022 2.643B
December 31, 2021 3.051B
December 31, 2020 1.830B
December 31, 2019 1.755B
December 31, 2018 1.416B
December 31, 2017 1.325B
December 31, 2016 1.048B
December 31, 2015 995.92M
December 31, 2014 855.51M
December 31, 2013 918.78M
December 31, 2012 806.18M
December 31, 2011 707.71M
December 31, 2010 637.42M
December 31, 2009 550.27M
December 31, 2008 516.29M
Date Value
December 31, 2007 513.05M
December 31, 2006 371.71M
December 31, 2005 248.54M
December 31, 2004 192.16M
December 31, 2003 199.64M
December 31, 2002 203.02M
December 31, 2001 148.67M
December 31, 2000 84.92M
December 31, 1999 72.18M
December 31, 1998 58.67M
December 31, 1997 51.62M
December 31, 1996 32.05M
December 31, 1995 37.80M
December 31, 1994 31.28M
December 31, 1993 19.27M
December 31, 1992 8.731M
December 31, 1991 5.851M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Gilead Sciences, Inc. 5.688B
Alnylam Pharmaceuticals, Inc. 1.320B
Sionna Therapeutics, Inc. 60.26M
Regeneron Pharmaceuticals, Inc. 5.306B
Biogen, Inc. 1.481B